Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
Synergy Pharmaceuticals stock has been one of my favorite topics recently. The company’s advancements with regard to their experimental drug, known as plecanatide, have been incredible. Now, the company is giving investors even more reason to put on the bullish face. They have brought on a new executive to help with the commercialization of the drug. Today, we’ll talk about who the new executive is, where his experience lies, and what we can expect from SGYP moving forward. So, let’s get right to it…
Troy Hamilton Has Joined Synergy Pharmaceuticals
Troy Hamilton will be joining Synergy Pharmaceuticals as the company’s Chief Commercial Officer. His responsibilities will be around strategy and execution of marketing, sales, and commerical operations and infrastructure for the United States launch of plecanatide. In a statement, Gary S. Jacob, Ph.D., Chairman and CEO of SGYP had the following to say…
“There has never been a more exciting time for Synergy than right now and Troy’s appointment strengthens our commitment to putting the highest level of leadership in place to best position plecanatide for a successful launch…Troy brings highly relevant and extensive commercial experience from his 19 years at Shire and J&J. We have a great product in plecanatide and Troy provides the creative vision and commercial expertise we need to extract optimal value and drive continued success.”
Following his appointment to the company, Troy Hamilton also had the following to say…
“I am thrilled to be joining Synergy…The U.S. constipation market is highly energized and the commercial outlook for a product like plecanatide is extremely promising. I look forward to the opportunity of working with the Synergy team to maximize plecanatide’s significant market potential, with the ultimate goal of serving the unmet needs of CIC and IBS-C patients.”
What Experience Does Troy Hamilton Offer?
Tory Hamilton has been in the pharmaceutical industry for more than 19 years. His experience in P&L responsibility, commercialization, partnerships, acquisitions, and global product launches is impeccable. Before joining SGYP, Mr. Hamilton held several commercial leadership roles at Shire Pharmaceuticals, Johnson & Johnson and other leading healthcare companies.
What We Can Expect From Synergy Pharmaceuticals Moving Forward
The appointment of Troy Hamilton to Synergy Pharmaceuticals is yet another reason I’m expecting growth. Since the release of the results of the first Phase 3 study into plecanatide, I’ve been convinced that SGYP has something big here. Now, with the appointment of Troy Hamilton, the company is showing that they have plans to bring the drug to its fullest potential and are willing to bring on new talent to make that happen. All in all, I think SGYP has massive upside potential moving forward.
What Do You Think?
Where do you think SGYP is headed and why? Let us know in the comments below!